ANNE VANLENT
CIK 1229243 · Exec VP & CFO · last filed 2026-06-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$683.0K
Companies
12
Total Filings
59
Lifetime Open-Market Net
-$130.4K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TRVI | Director | 20,983 | $18.48 | $387.8K | $50.0K | 10 | 2026-06-04 |
| APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted | Director | — | $0.39 | — | $0 | 9 | 2022-12-01 |
| Vaxart, Inc. (VXRT) Delisted | Director | — | $0.32 | — | $0 | 1 | 2019-06-14 |
| AVIR | Director | — | $4.76 | — | $0 | 2 | 2017-05-22 |
| NOVELION THERAPEUTICS INC. (NVLN) Delisted | Director | — | — | — | $0 | 1 | 2016-12-27 |
| Aegerion Pharmaceuticals, Inc. (AEGR) Delisted | Director | 0 | — | — | $0 | 3 | 2016-11-30 |
| Vaxart, Inc. (BOTA) Delisted | Director | 35,000 | — | — | $76.9K | 4 | 2015-08-13 |
| ONTX | Director | — | $13.46 | — | $0 | 3 | 2015-06-17 |
| Ocera Therapeutics, Inc. (TZYM) Delisted | Director | — | — | — | $0 | 2 | 2012-08-09 |
| IART | Director | 16,956 | $17.41 | $295.2K | -$250.3K | 8 | 2012-05-21 |
| PENWEST PHARMACEUTICALS CO (PPCO) Delisted | Director | 0 | — | — | -$7.0K | 8 | 2010-09-22 |
| BARRIER THERAPEUTICS INC (BTRX) Delisted | Exec VP & CFO | 148,852 | — | — | $0 | 2 | 2008-03-17 |
Recent Filings · Page 3 of 6
59 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-05-22 | AVIR | Grant (A) | — | $0 | EDGAR |
| 2017-03-02 | APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-12-27 | NOVELION THERAPEUTICS INC. (NVLN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-12-01 | — | Grant (A) | +4,102 | $0 | |
| 2016-11-30 | Aegerion Pharmaceuticals, Inc. (AEGR) Delisted | Disp (D) | −4,000 | $0 | EDGAR |
| 2016-08-18 | APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-06-15 | — | Grant (A) | — | $0 | |
| 2016-05-13 | AVIR | Grant (A) | — | $0 | EDGAR |
| 2015-08-13 | Vaxart, Inc. (BOTA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-06-29 | Aegerion Pharmaceuticals, Inc. (AEGR) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.